Histogen Inc. (HSTO)
- Previous Close
0.3501 - Open
0.4000 - Bid --
- Ask --
- Day's Range
0.3501 - 0.3501 - 52 Week Range
0.0500 - 1.0500 - Volume
6,951 - Avg. Volume
19,287 - Market Cap (intraday)
1.496M - Beta (5Y Monthly) 1.17
- PE Ratio (TTM)
-- - EPS (TTM)
-2.8100 - Earnings Date Apr 25, 2024 - Apr 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California. On April 18, 2024, Histogen Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of California.
www.histogen.comRecent News: HSTO
Performance Overview: HSTO
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HSTO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HSTO
Valuation Measures
Market Cap
1.50M
Enterprise Value
-3.08M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
78.77
Price/Book (mrq)
0.28
Enterprise Value/Revenue
-161.97
Enterprise Value/EBITDA
0.25
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-53.81%
Return on Equity (ttm)
-119.89%
Revenue (ttm)
19k
Net Income Avi to Common (ttm)
-12.38M
Diluted EPS (ttm)
-2.8100
Balance Sheet and Cash Flow
Total Cash (mrq)
4.57M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.78M